Nektar’s stock rises 51% on Phase II Rezpeg AD maintenance win

Nektar Therapeutics banal has rallied 51% aft its pb asset, rezpeg (rezpegaldesleukin), demonstrated imaginable crossed monthly and quarterly attraction dosing regimens during a Phase II proceedings successful atopic dermatitis (AD).

At the one-year constituent successful the REZOLVE-AD survey (NCT06136741), a 24 µg/kg dose of the T-regulatory (Treg) therapy continued to amusement illness power crossed 4 communal measures of AD illness severity. This includes Eczema Area Severity Index 75 and 90 scores (EASI-75; EASI-90), validated Investigator Global Assessment of Atopic Dermatitis (vIGA-AD) response, and Itch Numerical Rating Scale (NRS) response.

Of the patients connected the monthly dosing regimen who had achieved EASI-50 during the 16-week induction, 71% and 80% of patients achieved EASI-75 and EASI-90, respectively, aft a twelvemonth of dosing.

Rezpeg was likewise efficacious successful quarterly-dosed patients who met this criterion successful induction, with 83% and 78% of the cohort achieving EASI-75 and EASI-90 astatine the aforesaid clip point. Meanwhile, 22% fixed a monthly dose and 18% allocated to a quarterly docket achieved EASI-100, oregon full AD clearance, astatine week 52.

Rezpeg besides prompted 85% and 63% of patients, respectively, to execute vIGA-AD scores of 0 oregon 1 crossed the monthly and quarterly dosing schedules astatine 52 weeks, portion improving itch NRS scores successful 75% and 77% of patients.

Alongside its enactment successful responders, rezpeg besides offered benefits to erstwhile non-responders during the 36-week, blinded attraction play – with 33% achieving EASI-90 successful the monthly dosing cohort. 26% of patients allocated to the quarterly dosing docket experienced the aforesaid outcome.

The IL-2 receptor (IL-2R) pathway agonist was recovered to beryllium harmless and tolerable. The astir communal treatment-emergent adverse lawsuit (TEAE) was injection tract reactions – of which 77% were classed arsenic mild. There were nary cases of conjunctivitis, oral ulcers, erythema, cardiovascular adverse events oregon malignancies observed.

Investors look to beryllium pleased with the Phase II result for rezpeg successful AD, arsenic Nektar’s banal worth soared 51% aft the quality debuted – going from $37.07 astatine marketplace adjacent connected 9 February to $56.00 astatine marketplace unfastened connected 10 February. The company’s banal worth whitethorn person besides seen an summation owed to the commencement of an underwritten nationalist offering, which volition spot Nektar connection $3m of its shares successful communal banal to investors.

This follows the affirmative outcomes seen successful the aboriginal stages of the REZOLVE-AD study, which were announced successful June and September 2025, respectively. When information was presented astatine the 2025 European Academy of Dermatology and Venereology (EADV) Congress successful Paris, France, successful September 2025, Nektar’s banal roseate much than 150%.